You are here:     > Corporate Overview > NME & Specialty Pipeline

NME & Speciality Pipeline

Glenmark has a robust pipeline of nine compounds in various stages of clinical development, primarily focused in the areas of Respiratory, Dermatology, Oncology and Pain.

1. Non-core assets include GRC 17536, GBR 900 and GBR 500. These
three molecules and GRC 27864 are candidates for out-licensing
2. RyaltrisTM has been conditionally accepted as the brand name for
GSP 301 Nasal Spray by the US Food & Drug Administration (FDA)
3. Pipeline updated as of May 2018